CD159a (NKG2A) Antibody, anti-human, REAlease®
Synonyms: KLRC1, CD159a, NKG2, NKG2A
RECOMBINANT EXTENDED VALIDATION
Bioz Star91/100 Bioz rating
1 Citation
Clone:
REAL283
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD159a (NKG2A) Antibody, anti-human, REAlease®

Flow cytometry applications
APC
FITC
PE
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-115-983, 130-122-643, 130-116-062
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD159a (NKG2A)-APC (B) or with the corresponding REAL Control (A). REAlease CD159a (NKG2A)-APC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD159a (NKG2A)-APC (D). Cells were labeled with CD56 antibodies in addition and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Application imageView details view details

Application imageView details view details

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-115-983, 130-116-062
Testing grade:
Description:
Immunofluorescence analysis of a human tonsil cryosection fixed with ice-cold acetone. The section was stained using CD159a (NKG2A) Antibody, anti-human, APC (green) for 10 min at room temperature (A). CD159a (NKG2A) Antibody, anti-human, APC staining was released using the REAlease Release Reagent (B). Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application imageView details view details

Application imageView details view details
Extended validation for CD159a (NKG2A) Antibody, anti-human, REAlease®
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REAL283
REA110
high
131411
partial
Z199
high

Cells were incubated with an excess of purified unconjugated CD159a (NKG2A) (REAL283) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD159a (NKG2A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD159a (NKG2A) antibodies and with a suitable counterstaining. As a control, CD159a (NKG2A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for CD159a (NKG2A) Antibody, anti-human, REAlease®
Overview

Clone REAL283 is an antibody fragment derived from the full CD159a (NKG2A) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL283 recognizes CD159a, an inhibitory natural killer (NK) cell receptor. CD159a forms heterodimer with CD94 and contains a C-type lectin ectodomain. Inhibitory signal is transmitted by the heterodimer via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and upon ligand engagement, ITIMs are phosphorylated and transmit signal through docking of various tyrosine phosphatases. CD159a/CD94 binds non-classical MHC class I protein, HLA-E. Expression of CD159a is found mainly on NK cells and on subsets of CD8+ cells.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

KLRC1, CD159a, NKG2, NKG2A

Detailed product information

Technical specifications

Clone
REAL283
Clonality
monoclonal
Isotype control
Control Antibody
Host
cell line
Type of antibody
Releasable antibodies, Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD159a (NKG2A)
Distribution of antigen
NK cells, T cells, CD8+ T cells
RRID
AB_2751623, AB_2783970, AB_2751299, AB_2751308, AB_2783971, AB_2751296, AB_2751579, AB_2751305, AB_2783972
Resources for CD159a (NKG2A) Antibody, anti-human, REAlease®
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?